Innate Pharma (IPH) Leerink Global Healthcare Conference 2026 summary

Nectin-4 ADC (IPH4502) program updates

• Differentiation from competitors is based on a superior antibody and linker, enabling efficacy in low Nectin-4 expression tumors and a potentially wider therapeutic window compared to Lilly and Hengrui compounds.

• Ongoing phase I basket study uses adaptive design to identify promising tumor types, with expansion to 120+ patients and focus on triple-negative breast, prostate, and non-small cell lung cancers.

• Study aims to enrich for PADCEV-treated patients, targeting a post-PADCEV label and potential accelerated approval in this high unmet need setting.

• Decision pending on timing of data release: early basket data or more robust, tumor-specific results with longer follow-up, with a preference for the latter.

• Study remains on track, with strong patient demand and rapid cohort enrollment.

Lacutamab clinical and strategic progress

• Accelerated approval path agreed with FDA for Sézary syndrome, with a phase III umbrella protocol including cohorts for Sézary and mycosis fungoides, both using active comparators.

• Confirmatory study ready to initiate pending funding, with BLA submission targeted for early 2027 and potential approval by late 2027.

• Strategic partnership, royalty financing, and equity raise options are being evaluated to fund the program.

• Strong PFS data in mycosis fungoides supports confidence in outperforming standard of care in the confirmatory trial.

• Investigator-initiated studies planned to explore use in earlier-stage patients, aiming to prevent disease progression and expand market potential.

Lacutamab in PTCL and future directions

• Phase II investigator-initiated study ongoing in PTCL with GemOx combination, with data expected before year-end and potential for first-line development.

• LYSA group, with a strong track record, is leading the study and aims to develop an L-CHOP regimen for PTCL.

• Interim analysis has been seen by the company, but not yet by regulators.